VVUS VIVUS Inc.

2.79
0  0%
Previous Close 2.79
Open 2.77
Price To Book -0.47
Market Cap 29,693,169
Shares 10,642,713
Volume 22,814
Short Ratio
Av. Daily Volume 74,939
Stock charts supplied by TradingView

NewsSee all news

  1. VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

    CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper

  2. New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa

    -Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE)

  3. VIVUS Reports Third Quarter 2019 Financial Results

    CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on

  4. VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors

    CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of

  5. VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019

    CAMPBELL, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

    CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper

  2. New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa

    -Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE)

  3. VIVUS Reports Third Quarter 2019 Financial Results

    CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on

  4. VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors

    CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of

  5. VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019

    CAMPBELL, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on

  6. VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit

    CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate in a panel

  7. VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

    CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland,

  8. VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

    -Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) --

  9. VIVUS to Present at Upcoming Conferences

    CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the

  10. VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019

    -Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. 27, 2019 (GLOBE